Our Business

EcoBiotics is a specialist drug discovery company

We build long-term value for our shareholders by discovering small molecule drug candidates in a range of therapeutic areas. We then seek to:

  • license these chemicals to pharmaceutical companies for further development in return for sign-on fees, milestone payments and royalties on retail sales; or
  • form strategic alliances with companies with complementary skills and technologies to collaboratively develop our products.

We also use our expertise in drug discovery to:

  • identify and provide 'evidence-based' science to underpin commercialisation of new nutraceuticals and cosmetic ingredients; and
  • offer contract R&D discovery services to external clients.



Our corporate mission is to:

Improve the quality of life for people and companion animals by discovering new medicines and by contributing to understanding and conservation of tropical rainforests.



We differ from many biotechnology companies in that we:

  1. focus on discovery and early product development;
  2. continually add to our diverse portfolio in a range of therapeutic areas;
  3. use our drug discovery expertise to develop and commercialise new nutraceuticals and cosmetic ingredients; and
  4. offer contract R&D discovery services to external clients.

This strategy:

  • greatly reduces our reliance on single products (which by the nature of the industry have extremely high attrition rates) and
  • gives us the opportunity to generate early, multiple and staged revenue streams from a diverse client base.


Company Milestones


  • Validation of our EcoLogic™ discovery technology
  • Diverse portfolio of chemicals in 4 therapeutic areas
  • Evaluation & collaboration deals for nutraceuticals & cosmetic ingredients

Near Term

  • Licensing deals
  • First products reach clinical phase I
  • Pharmaceutical discovery R&D deals
  • First nutraceuticals and cosmetic ingredients reach market


  • Out-licensed pharmaceuticals reach retail market
  • Internal R&D delivers products to clinical phase II